Laura is the vice president of content for The American Journal of Managed Care® (AJMC®) and all its brands, including The American Journal of Accountable Care®, Evidence-Based Oncology™, and The Center for Biosimilars®. She has been working on AJMC® since 2014 and has been with AJMC®’s parent company, MJH Life Sciences®, since 2011.
She has an MA in business and economic reporting from New York University. You can connect with Laura on LinkedIn or Twitter.
Patients With COPD Face High Risk of Adverse Drug Reactions Due to Multimorbidity
Multimorbidity is common in patients with chronic obstructive pulmonary disease (COPD), and is associated with high levels of polypharmacy, which can lead to an increased risk of adverse drug reactions.
Senate, House Pass Spending Bill With Health Program Funding After Brief Shutdown
After a brief shutdown in the dead of night, the Senate passed a spending bill, which was the result of a deal reached by Republicans and Democrats to fund military and domestic programs for 2 years. The House passed the bill shortly after.
Long-Term Follow-Up of CAR T in ALL Indicates Early Treatment Extends Survival
A long-term follow-up analyzing the toxic effects and results from a phase 1 clinical trial of adult patients with relapsed B-cell acute lymphoblastic leukemia (ALL) who were treated with CD19-specific chimeric antigen receptor (CAR) T cells found patients with low disease burden had a longer medial overall survival and a lower incidence of toxicity.
Shifting Hospital Care to the Home Improved Quality of Life for Patients With COPD
Shifting care for patients with chronic obstructive pulmonary disease (COPD) from the hospital to the home reduced hospital readmissions by 64% and emergency department visits by 52%, a Canadian program found.
Gut Microbiome Diversity Associated With Blood Infections in Pediatric Patients With Cancer
Every year, central lines are associated with causing blood infections in an estimated 400,000 patients with cancer. However, new research has found that changes in the microbiome may be responsible for some or many of the infections usually attributed to central lines.
Kyprolis Label Gets Updated Improved Survival Data for Patients With Relapsed/Refractory MM
The FDA has approved a supplemental New Drug Application to add new overall survival (OS) data for carfilzomib (Kyprolis). The label will now show that carfilzomib and dexamethasone reduced the risk of death by 21% and increased OS by 7.6 months compared with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (MM).
Precursor to Blood Cancer Puts Patients at Risk Indefinitely, Study Finds
Despite years of stability, patients with monoclonal gammopathy of undetermined significance (MGUS) are at risk of progressing to multiple myeloma or another blood cancer, according to a long-term follow-up study published in New England Journal of Medicine. MGUS usually causes no problems, but it is a precursor to cancer.
VA Won't Research Medical Marijuana for Chronic Pain or PTSD Among Veterans
An inquiry by 10 Democrats on the House Committee on Veterans’ Affairs into whether or not the Department of Veterans Affairs (VA) would research medical marijuana in veterans suffering from posttraumatic stress disorder (PTSD) and chronic pain was met with denial.
Express Scripts Is Built for the Future of Healthcare, Says CEO Wentworth
It’s true, pharmacy benefit managers (PBMs) are complicated, admitted Tim Wentworth, president and CEO of Express Scripts, during his presentation at the JP Morgan Healthcare Conference in San Francisco, California. However, the company is built to succeed in the future of healthcare, he said.
Gates Discusses the Hope of Using Immuno-Oncology for HIV Breakthroughs, and More
While public funding through the National Institutes of Health has created a foundation for healthcare research, the private sector can benefit from getting more involved, said Bill Gates, philanthropist and co-founder of Microsoft.
How Value Frameworks Define Durable Survival of New Immuno-Oncology Agents
New immuno-oncology agents are providing durable survival for some patients, but the cost of these treatments is very high, which is a cause for concern. In a new study in JAMA Oncology, researchers sought to assess how value frameworks defined the efficacy of new immuno-oncology agents.
Can Technology-Based Interventions Be Used to Improve Adherence Among Adolescents?
Low medication adherence is a problem in healthcare, in general. However, adolescents with chronic health conditions also have low adherence, but they are at a critical age when they can create routines and health behaviors that optimize disease management as they become adults.
Top 2017 AJMC® Articles Identify Ways to Reduce Costs and Improve Care Outcomes
With reimbursement increasingly tied to outcomes, health systems and practices are trying to find ways to reduce costs while delivering better care. Some of the most-read articles in The American Journal of Managed Care® (AJMC®) in 2017 included an analysis of the benefits of treating everyone with hepatitis C with new, expensive treatments, a program to reduce readmissions, and a look at the impact of value-based contracting in Medicare Advantage.
Diagnosing Congenital Neutropenia
Physicians caring for patients with severe congenital neutropenia should be ready to detect issues with multiple systems in the body, explained Seth Corey, MD, of the Virginia Commonwealth University and the Massey Cancer Center & Children's Hospital of Richmond, during a session at the 59th American Society of Hematology Annual Meeting and Exposition in Atlanta, Georgia.
Developing State-Level Programs for Care of Complex Populations
Using lessons learned from the past 4 years of working with 10 states and Puerto Rico, the National Governors Association Center for Best Practices Health Division has released a road map to guide states in establishing state-level solutions to care for complex populations.
New SGLT2 Competitor Steglatro Approved for Type 2 Diabetes
A new sodium-glucose co-transporter 2 medication to treat type 2 diabetes is joining the field: the FDA approved ertugliflozin (Steglatro) from Merck and Pfizer as a single therapy and in combination with Merck’s sitagliptin (Januvia), a DPP-4 inhibitor, or with metformin.
AJMC®tv Interviews, December 2017
AJMC®TV interviews let you catch up on what’s new and important about changes in healthcare, with insights from key decision makers—from the clinician, to the health plan leader, to the regulator. When every minute in your day matters, AJMC®TV interviews keep you informed. Access the video clips at ajmc.com/interviews.